Results in 20 minutes.

Can improve patient outcomes

By providing faster results, medical professionals can offer earlier therapeutic interventions without needing additional resources or third party labs. This can help redirect critical patients.


Less invasive testing.

A quick process with minimal discomfort

No uncomfortable nasal swabs or blood draw required. A few drops of blood can determine whether a patient has been exposed to the virus within the past 4 to 24 days or longer.


Determine the infection time from 4-24 days.

Diagnostic Assay

By measuring the concentration of these particular antibodies, the SARS-CoV-2 Rapid Test can determine in 20 minutes whether you have been exposed to the virus within the past 4 to 24 days or even longer.


Designed for healthcare professionals.

Designed for healthcare professionals

The COVID-19 Rapid Test is intended for the use by trained healthcare professionals. The COVID-19 Rapid Test is only for use under the Food and Drug Administration's Emergency Use Authorization.

The Vivera® Pharmaceuticals COVID-19 Rapid Test is an in-vitro diagnostic test for the qualitative detection of IgM and IgG antibodies to the SARS-CoV-2 virus.

Dedicated to putting patients first.

Interview with Tucker Carlson Tonight

News & Media

CBS discussing CoV-2 Rapid Test

Under the revised FDA March 16, 2020 Guidance Vivera Pharmaceuticals is able to offer the Vivera Pharmaceuticals CoV-2 Rapid Test.
This test has not been reviewed by the FDA.
Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.